B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

What was studied

This is a guideline summary on mantle cell lymphoma (MCL). MCL is a mixed subtype of B-cell lymphoma. The text is a selection from the NCCN Guidelines for B-Cell Lymphomas. The source is version 4.2026. It focuses on diagnosis and treatment of MCL.

What they found

Care for new MCL has changed in recent years. New parts include covalent BTK inhibitors. Tests for measurable residual disease are also used. Maintenance or continuous therapy is planned in advance. BTK inhibitor plans fit untreated MCL with TP53 mutations. After covalent BTK inhibitors, refractory disease can be treated with pirtobrutinib or CAR T-cell therapy.

What it means for patients

The authors said care for new MCL has changed a lot lately. They said BTK inhibitor plans are good options for untreated MCL with TP53 mutations. They said pirtobrutinib and CAR T-cell therapy are effective options after covalent BTK inhibitors.

Why it is not certain yet

This is guideline text, not a study. The abstract gives no trial data or patient numbers. It names no single study. It covers only mantle cell lymphoma. Guidance can change as new data arrive.

Source

B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

We restate facts from the source record in our own words. The original wording belongs to its publisher.